DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02118376

UnknownPhase NA

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•Female

Primary endpoint

•Dual energy X-ray absorptiometry

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02118376

Timeline

Milestones

Study first posted2014-04-21estimated
Last update posted2014-04-21estimated
Study start2014-08 (month precision)
Primary completion2014-12estimated (month precision)
Study completion2014-12estimated (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Clinical diagnosis of overweight and type 2 diabetes mellitus

Exclusion criteria

•Poor body condition (severe liver and kidney dysfunction)
•Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach operation, malignant tumor, previous use of systemic corticosteroids (local or inhalation of exceptions) heart function or niacin, incomplete
•serious endocrine disease
•genetic disease

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
MASH / liver
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Dual energy X-ray absorptiometry

Time frame:3 month

descriptive

MASH / liver

1 endpoint
Other/protocol endpoint/low confidence

lab testing

Time frame:3 months

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

lab testing

Time frame:3 month

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.